As 2019 begins, STAT reporters are taking a look at the stories they’re most eager to track during the year. Find all our “three to watch” series here.
WASHINGTON — Drug pricing is on the agenda here in 2019. But with Republicans controlling the Senate and Democrats controlling the House — and neither party fully on board with the White House’s work on drug pricing — the next two years are unlikely to be an era of wholesale change for the country’s health care system or how prescription medicines are priced.
About the Author Reprints
